NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001739

Registered date:27/02/2009

The influence of azelnidipine on plasma renin activity and plasma aldosterone concentration in hypertensive patients.

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedEssential hypertension
Date of first enrollment2007/10/01
Target sample size40
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)PRA/PAC was measured in 10 of essential hypertensive patients. Then, 16 mg of azelnidipine a day was started to administer for 4 weeks. After this period, PRA/PAC was measured again. PRA/PAC was measured in 10 of essential hypertensive patients who have been treated with amlodipine. Then, 16 mg of azelnidipine a day was started to administer in stead of amlodipine for 4 weeks. After this period, PRA/PAC was measured again. PRA/PAC was measured in 10 of essential hypertensive patients who have been treated with manidipine. Then, 16 mg of azelnidipine a day was started to administer in stead of manidipine for 4 weeks. After this period, PRA/PAC was measured again. PRA/PAC was measured in 10 of essential hypertensive patients who have been treated with nifedipine. Then, 16 mg of azelnidipine a day was started to administer in stead of nifedipine for 4 weeks. After this period, PRA/PAC was measured again.

Outcome(s)

Primary OutcomePlasma renin activity, plasma aldosterone concentration
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum50years-old
Age maximum90years-old
GenderMale and Female
Include criteria
Exclude criteriaSecondary hypertension

Related Information

Contact

public contact
Name
Address 1-1-1, Honjo, Kumamoto Japan
Telephone 096-373-5169
E-mail
Affiliation Graduate School of Medical Sciences, Kumamoto University Department of Metabolic Medicine
scientific contact
Name Tatsuya Kondo
Address 1-1-11-1-1, Honjo, Kumamoto Japan
Telephone
E-mail
Affiliation Graduate School of Medical Sciences, Kumamoto University Department of Metabolic Medicine